Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
5.20
-0.36 (-6.47%)
At close: Apr 14, 2026, 4:00 PM EDT
5.20
0.00 (0.00%)
After-hours: Apr 14, 2026, 5:59 PM EDT
Zentalis Pharmaceuticals Employees
Zentalis Pharmaceuticals had 106 employees as of December 31, 2025. The number of employees decreased by 60 or -36.14% compared to the previous year.
Employees
106
Change (1Y)
-60
Growth (1Y)
-36.14%
Revenue / Employee
n/a
Profits / Employee
-$1,293,019
Market Cap
368.84M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 106 | -60 | -36.14% |
| Dec 31, 2024 | 166 | -2 | -1.19% |
| Dec 31, 2023 | 168 | 12 | 7.69% |
| Dec 31, 2022 | 156 | -21 | -11.86% |
| Dec 31, 2021 | 177 | 53 | 42.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| REGENXBIO | 371 |
| Absci | 140 |
| Sutro Biopharma | 137 |
| Aura Biosciences | 113 |
| Assembly Biosciences | 73 |
| Armata Pharmaceuticals | 60 |
| Lexeo Therapeutics | 59 |
ZNTL News
- 4 days ago - What's Behind The Surge In Zentalis Stock? - Benzinga
- 5 days ago - Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer - GlobeNewsWire
- 13 days ago - Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 19 days ago - Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates - GlobeNewsWire
- 4 weeks ago - Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire
- 7 weeks ago - Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference - GlobeNewsWire
- 3 months ago - Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026 - GlobeNewsWire